News

An extensive data collection on Juvenile Myelomonocytic Leukemia is now available. The data were made available thanks to funding from the Cancer Childhood Data Initiative, offering researchers greater insight into the genetic, epigenetic, and biochemical basis of this Ras-driven leukemia.

NCI’s Imaging Data Commons has released several notable updates, including the release of three collections by the Human Tumor Atlas Network, which comprise a new multichannel fluorescence imaging data set.

Celebrate the NCI team that recently received a 2022 FedHealthIT Innovation Award for their commitment to advancing cancer research through work proteomics efforts such as the Proteomic Data Commons.

Using this knowledgebase, researchers may search for associations between molecular drug targets, diseases, and drugs specific for childhood cancers.

With funding from NCI’s Childhood Cancer Data Initiative, researchers at Oregon Health & Science University’s Knight Cancer Institute have shared new data from pediatric, adolescent, and young adult patients with Acute Myeloid Leukemia.

NIH has issued a request for public comments on draft supplemental information to the NIH Policy for Data Management and Sharing. Responses will be accepted through June 27, 2022.

Genomic studies of childhood and rare cancers got a major boost, as a new optimized workflow for managing these data was recently reported in “Nature Communications.” And, thanks to funding by NCI’s Childhood Cancer Data Initiative, it’s easier and faster to share those data with the cancer research community.

In this JAMA Oncology Viewpoint opinion article, Dr. Jill Barnholtz-Sloan, NCI’s associate director for Informatics and Data Science, discusses NCI’s large-scale data sharing and access efforts. She also stresses that as we continue to generate cancer data, free and open scientific data should be treated as a public good.

NCI has just launched the Molecular Characterization Initiative, fostering data sharing in childhood cancer research. This program offers tumor molecular characterization to children, adolescents, and young adults who have been diagnosed with central nervous system tumors and are being treated at hospitals affiliated with an NCI-supported clinical trials group, “Children’s Oncology Group.” The DNA and RNA in participants' tumors are analyzed through this voluntary, free program. Once data is available, cancer researchers will be able to access the data via the Cancer Research Data Commons.

CBIIT Director, Dr. Tony Kerlavage, sat down recently for a podcast examining the evolution of NCI’s Data Commons. He tracked the development of the Cancer Research Data Commons, from its early pilots to today’s cloud-based infrastructure, with repositories of diverse data and more than 1,000 tools and resources.